| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 21.33 | 24.27 | 18.97 | -14.12 |
Op profit growth | 76.64 | 122.26 | 93.32 | -67.16 |
EBIT growth | 86.92 | 176.46 | 176.91 | -81.47 |
Net profit growth | 103.84 | 255.25 | 272.68 | -88.74 |
Profitability ratios (%) | ||||
OPM | 24.67 | 16.95 | 9.47 | 5.83 |
EBIT margin | 22.53 | 14.62 | 6.57 | 2.82 |
Net profit margin | 17.33 | 10.31 | 3.6 | 1.15 |
RoCE | 37.8 | 25.56 | 10.32 | 3.9 |
RoNW | 7.83 | 5.28 | 1.82 | 0.49 |
RoA | 7.26 | 4.5 | 1.41 | 0.39 |
Per share ratios (₹) | ||||
EPS | 5.83 | 2.95 | 0.87 | 0 |
Dividend per share | 0.25 | 0.1 | 0.05 | 0.05 |
Cash EPS | 4.94 | 2.2 | 0.14 | -0.51 |
Book value per share | 21.65 | 15.53 | 11.5 | 10.58 |
Valuation ratios | ||||
P/E | 8.56 | 4.71 | 36.37 | 0 |
P/CEPS | 10.1 | 6.29 | 212.31 | -90.8 |
P/B | 2.3 | 0.89 | 2.75 | 4.45 |
EV/EBIDTA | 5.38 | 2.62 | 15.81 | 38.91 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 7.48 | 192.97 |
Tax payout | -21.05 | -23.17 | -28.1 | -23.91 |
Liquidity ratios | ||||
Debtor days | 68.33 | 67.62 | 84.88 | 110.58 |
Inventory days | 85.68 | 74 | 81.62 | 85.13 |
Creditor days | -49.11 | -36.45 | -52.92 | -70.92 |
Leverage ratios | ||||
Interest coverage | -38.83 | -18.96 | -5.87 | -3.19 |
Net debt / equity | -0.2 | -0.1 | 0.16 | 0.19 |
Net debt / op. profit | -0.52 | -0.33 | 0.9 | 1.88 |
Cost breakup (₹) | ||||
Material costs | -43.23 | -48.04 | -57.31 | -59.79 |
Employee costs | -14.33 | -14.84 | -16.18 | -19.51 |
Other costs | -17.74 | -20.16 | -17.01 | -14.85 |
The inspection by the USFDA had taken place between April 16 and 24. After the visit, the company disclosed one observation under Form 483.
The block deal has been launched at a floor price of ₹249.95 per share, signaling a strategic partial exit by the investor.
Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
